Moderna, Inc. (MRNA)
MRNA Stock Price Chart
Explore Moderna, Inc. interactive price chart. Choose custom timeframes to analyze MRNA price movements and trends.
MRNA Company Profile
Discover essential business fundamentals and corporate details for Moderna, Inc. (MRNA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
7 Dec 2018
Employees
5.80K
Website
https://www.modernatx.comCEO
Stephane Bancel
Description
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
MRNA Financial Timeline
Browse a chronological timeline of Moderna, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 29 Apr 2026
Upcoming earnings on 12 Feb 2026
Upcoming earnings on 6 Nov 2025
EPS estimate is -$1.94.
Earnings released on 1 Aug 2025
EPS came in at -$2.13 surpassing the estimated -$2.99 by +28.76%, while revenue for the quarter reached $142.00M , missing expectations by -84.56%.
Earnings released on 1 May 2025
EPS came in at -$2.52 surpassing the estimated -$2.92 by +13.70%, while revenue for the quarter reached $107.00M , missing expectations by -8.35%.
Earnings released on 14 Feb 2025
EPS came in at -$2.50 surpassing the estimated -$2.68 by +6.72%, while revenue for the quarter reached $956.00M , beating expectations by +1.40%.
Earnings released on 7 Nov 2024
EPS came in at $0.03 surpassing the estimated -$1.91 by +101.57%, while revenue for the quarter reached $1.86B , beating expectations by +48.39%.
Earnings released on 1 Aug 2024
EPS came in at -$3.33 surpassing the estimated -$3.35 by +0.60%, while revenue for the quarter reached $241.00M , beating expectations by +87.68%.
Earnings released on 2 May 2024
EPS came in at -$3.07 surpassing the estimated -$3.56 by +13.76%, while revenue for the quarter reached $167.00M , beating expectations by +79.07%.
Earnings released on 22 Feb 2024
EPS came in at $0.55 surpassing the estimated -$0.97 by +156.70%, while revenue for the quarter reached $2.81B , beating expectations by +12.02%.
Earnings released on 2 Nov 2023
EPS came in at -$1.39 surpassing the estimated -$2.01 by +30.85%, while revenue for the quarter reached $1.83B , beating expectations by +38.27%.
Earnings released on 3 Aug 2023
EPS came in at -$3.62 surpassing the estimated -$3.84 by +5.73%, while revenue for the quarter reached $344.00M , beating expectations by +7.62%.
Earnings released on 4 May 2023
EPS came in at $0.19 surpassing the estimated -$1.77 by +110.73%, while revenue for the quarter reached $1.84B , beating expectations by +56.01%.
Earnings released on 23 Feb 2023
EPS came in at $3.61 falling short of the estimated $4.68 by -22.86%, while revenue for the quarter reached $5.08B , beating expectations by +1.33%.
Earnings released on 3 Nov 2022
EPS came in at $2.53 falling short of the estimated $3.29 by -23.10%, while revenue for the quarter reached $3.22B , missing expectations by -8.69%.
Earnings released on 3 Aug 2022
EPS came in at $5.24 surpassing the estimated $4.55 by +15.16%, while revenue for the quarter reached $4.57B , beating expectations by +11.45%.
Earnings released on 4 May 2022
EPS came in at $8.58 surpassing the estimated $5.21 by +64.68%, while revenue for the quarter reached $5.94B , beating expectations by +41.30%.
Earnings released on 24 Feb 2022
EPS came in at $11.29 surpassing the estimated $9.90 by +14.04%, while revenue for the quarter reached $6.95B , beating expectations by +2.23%.
Earnings released on 4 Nov 2021
EPS came in at $7.70 falling short of the estimated $9.05 by -14.92%, while revenue for the quarter reached $4.83B , missing expectations by -25.09%.
Earnings released on 5 Aug 2021
EPS came in at $6.46 surpassing the estimated $5.96 by +8.39%, while revenue for the quarter reached $4.22B , beating expectations by +0.18%.
Earnings released on 6 May 2021
EPS came in at $2.84 surpassing the estimated $2.39 by +18.83%, while revenue for the quarter reached $1.74B , missing expectations by -27.80%.
Earnings released on 25 Feb 2021
EPS came in at -$0.69 falling short of the estimated -$0.25 by -176.00%, while revenue for the quarter reached $229.38M , missing expectations by -50.11%.
Earnings released on 29 Oct 2020
EPS came in at -$0.59 falling short of the estimated -$0.43 by -37.21%, while revenue for the quarter reached $12.22M , missing expectations by -89.39%.
MRNA Stock Performance
Access detailed MRNA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.